Anzeige
Mehr »
Freitag, 07.08.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XCF2 | ISIN: US09062W2044 | Ticker-Symbol: BJX1
Tradegate
06.08.26 | 12:15
29,400 Euro
-0,68 % -0,200
1-Jahres-Chart
BIOLIFE SOLUTIONS INC Chart 1 Jahr
5-Tage-Chart
BIOLIFE SOLUTIONS INC 5-Tage-Chart
RealtimeGeldBriefZeit
29,40030,00010:05
29,40029,80010:06

Aktuelle News zur BIOLIFE SOLUTIONS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoBioLife Solutions, Inc.: BioLife Solutions Reports Second Quarter 2026 Financial Results60Total revenue of $28.5 million, up 21% over Q2 2025 GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65% GAAP net income of $45.1 million, inclusive...
► Artikel lesen
MoBIOLIFE SOLUTIONS INC - 8-K, Current Report1
23.07.TD Cowen downgrades BioLife Solutions stock rating on Repligen deal2
BIOLIFE SOLUTIONS Aktie jetzt für 0€ handeln
23.07.Übernahme durch Repligen: TD Cowen stuft BioLife Solutions Aktie herab2
22.07.BIOLIFE SOLUTIONS INC - 8-K, Current Report1
22.07.Repligen builds in cell therapy with $1.5bn BioLife Solutions takeover4
22.07.Repligen Strengthens Cell Therapy Portfolio With BioLife Solutions Acquisition3
22.07.Repligen to buy BioLife Solutions in $1.5 billion deal to expand cell therapy business3
22.07.Repligen To Acquire BioLife Solutions In $1.5 Billion Cash-and-Stock Deal2
22.07.Repligen to acquire BioLife Solutions for $1.5 billion1
22.07.Repligen to buy BioLife Solutions in $1.5B stock-and-cash deal4
22.07.Repligen Corporation: Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media426Fast-tracks Repligen's leadership and customer solution offering in high-growth cell therapy market by adding BioLife's differentiated, high-margin recurring revenue business BioLife...
► Artikel lesen
03.06.BIOLIFE SOLUTIONS INC - 8-K, Current Report1
07.05.BioLife Solutions, Inc.: BioLife Solutions Reports First Quarter 2026 Financial Results291Total revenue of $27.5 million, up 25% over Q1 2025 GAAP gross margin and non-GAAP adjusted gross margin of 64% GAAP net income of $1.2 million and non-GAAP adjusted...
► Artikel lesen
07.05.BIOLIFE SOLUTIONS INC - 10-Q, Quarterly Report1
07.05.BIOLIFE SOLUTIONS INC - 8-K, Current Report1
28.04.BIOLIFE SOLUTIONS INC - 10-K/A, Annual Report-
27.02.BioLife Solutions outlines 17-20% revenue growth target for 2026 while expanding commercial customer mix4
26.02.Earnings Call Transkript: BioLife Solutions übertrifft im Q4 2025 die Gewinnerwartungen3
26.02.BioLife Solutions GAAP EPS of $0.04 beats by $0.06, revenue of $24.76M beats by $0.75M1
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1